COMBAT-COVID
In mechanically ventilated patients with COVID-19 and severe endotheliopathy, does prostacylin compared with placebo, improve days alive without ventilation by day 28?
Continue reading »A compendium of critical appraisals in Intensive Care Medicine research and related specialties
A collection of TBL summaries relevant to Intensive Care Medicine
In mechanically ventilated patients with COVID-19 and severe endotheliopathy, does prostacylin compared with placebo, improve days alive without ventilation by day 28?
Continue reading »
In patients with out-of-hospital cardiac arrest, does calcium compared with placebo, improve sustained return of spontaneous circulation?
Continue reading »
In patients near end of life, does subcutaneous scopolamine butylbromide compared with placebo, reduce the incidence of death rattle?
Continue reading »
Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial Anderson et al. JAMA 2021. doi:10.1001/jama.2021.16628 Clinical Question In adult patients suffering an in-hospital cardiac arrest (IHCA) does the use of vasopressin and methylprednisolone compared to a placebo result in increased rates of return of spontaneous circulation (ROSC)? […]
Continue reading »
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial @PeterHorby. medRxiv pre-print 2021 doi: https://doi.org/10.1101/2021.06.15.21258542 Clinical Question In hospitalised patients with COVID-19, does the addition of monoclonal antibodies REGEN-COV (carsirivimab & imdevimab) to standard care, compared with standard care alone, improve 28 day mortality? Background Monoclonal antibodies have been shown to be […]
Continue reading »
In mechanically ventilated patients with acute hypoxaemic respiratory failure, does lowering tidal volume using extracorporeal carbon dioxide removal, compared with conventional low tidal volume ventilation, improve day 90 all-cause mortality?
Continue reading »
In patients with severe COVID, does 12mg dexamethasone vs 6mg dexamethasone increase the number of days alive without life support at 28 days?
Continue reading »
In hospitalised adult patient with COVID-19, does baricitinib compared with placebo decrease a composite outcome of progression of illness and mortality?
Continue reading »
Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation Desch S et al. NEJM 2021. DOI: 10.1056/NEJMoa2101909 Clinical Question In adults > 30 years old suffering out-of-hospital cardiac arrest (OOHCA) without ST elevation on their ECG does routine immediate coronary angiography compared to a delayed or selective approach to coronary angiography improve 30-day all-cause mortality? Background The DISCO pilot study showed […]
Continue reading »
Milrinone as compared with Dobutamine in the Treatment of Cardiogenic Shock Matthew. N Engl J Med 2021; 385:516-525, doi: 10.1056/NEJMoa2026845 Clinical Question In patients with cardiogenic shock, does milrinone as compared with dobutamine improve the composite outcome of in-hospital death, resuscitated cardiac arrest, receipt of cardiac transplant or mechanical circulatory support, non-fatal myocardial infarction, cerebrovascular event or renal replacement therapy? […]
Continue reading »